Lead Product(s) : Zelicapavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Enanta Reports Positive Phase 2 Results for Zelicapavir in Respiratory Syncytial Virus
Details : EDP-938 (zelicapavir) is a RSV N-protein inhibitor, small molecule drug candidate. It is being evaluated for the treatment of respiratory syncytial virus infection.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2024
Lead Product(s) : Zelicapavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zelicapavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
Details : Zelicapavir is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Syncytial Virus Infections.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : Zelicapavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zelicapavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EDP-938 is a nanomolar inhibitor of both RSV-A and RSV-B activity, in treatment of adults with acute respiratory syncytial virus (RSV) infection who are at high risk of complications.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 03, 2022
Lead Product(s) : Zelicapavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zelicapavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In this low-risk patient population which had mild, self-resolving upper respiratory tract infection, EDP-938 did not meet the primary endpoint of reduction in total symptom score compared to placebo, or the secondary antiviral endpoints.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 18, 2022
Lead Product(s) : Zelicapavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zelicapavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Completes enrollment for RSVP, a phase 2 study of EDP-938 in community-acquired respiratory syncytial virus infection in an adult population; plans to report topline data in the second quarter of 2022.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 06, 2022
Lead Product(s) : Zelicapavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable